Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2008
Highlights from the Q2 2008 review of device and diagnostics dealmaking: financing for medical device firms was down 9% from the first quarter to $838mm, which consisted mainly of late-stage venture rounds at 43% of the total. Big Pharma was surprisingly active in device acquisitions, with Novartis buying 25% of surgical instruments maker Alcon, and BMS selling off ConvaTec to private equity as part of its "string of pearls" strategy to focus on biotech. Two FOPOs dominated the $300mm financing the IVD/Research industry, while Invitrogen's $6.4bn stock swap for Applera's Applied Biosystems represented 90% of the M&A dollar volume.
In this issue, we present a review of medical device and in
vitro diagnostics/research dealmaking for the second quarter of
2008. Our data are derived from FDC-Windhover's Strategic
Transactions.
Amanda Micklus and Maureen Riordan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
